Back to Research Hub
Revolution Medicines, Inc.
RVMD
$149.55+1.06 (+0.71%)
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and…
StreetsValue research for Revolution Medicines, Inc. (RVMD)
Members get the full report for Revolution Medicines, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.